Antibodies against interferon-beta in multiple sclerosis

被引：19

作者：

Aarskog, Nina Karin ^{[1
]}

Maroy, Tove ^{[1
]}

Myhr, Kjell-Morten ^{[1
,2
]}

Vedeler, Christian A. ^{[1
,2
]}

机构：

[1] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway

[2] Univ Bergen, Dept Clin Med, N-5021 Bergen, Norway

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2009年 / 212卷 / 1-2期

关键词：

Multiple sclerosis; Interferon-beta; ELISA; Real-time PCR; NEUTRALIZING ANTIBODIES;

D O I：

10.1016/j.jneuroim.2009.04.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We measured the frequency of binding antibody (BAB) and neutralizing antibody (NAB) against interferon-beta (IFN-beta) in sera from 827 patients with relapsing-remitting multiple sclerosis (RRMS) using various IFN-beta medications. Of the 827 patients, 363 (43.9%) had serum BAB after more than 12 months of IFN-beta treatment. Of the 363 BAB-positive sera, we analyzed 137 for BAB using a myxovirus-resistant protein A (MxA) protein induction assay (ELISA) and an MxA messenger RNA (mRNA) induction assay (real-time polymerase chain reaction (PCR)). We obtained similar results for each serum in both NAB assays, indicating a good correlation between transcription and translation of MxA. We tested all 363 sera by real-time PCR, and NAB was present in 70.8% of BAB-positive sera, or 31.1% of the 827 patients with relapsing-remitting multiple sclerosis (RRMS). Real-time PCR offers several advantages for measuring NAB compared with the MxA protein induction enzyme-linked immunosorbent assay and should be used routinely for NAB among patients with MS using IFN-beta treatment. (C) 2009 Elsevier B.V. All rights reserved.

引用

页码：148 / 150

页数：3

共 8 条

[1] Interferon-β treatment for multiple sclerosis [J].

Bermel, Robert A. ;

Rudick, Richard A. .

NEUROTHERAPEUTICS, 2007, 4 (04) :633-646

[2] Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta [J].

Bertolotto, A. ;

Sala, A. ;

Caldano, M. ;

Capobianco, M. ;

Malucchi, S. ;

Marnetto, F. ;

Gilli, F. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2007, 321 (1-2) :19-31

[3] Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis [J].

Gilli, F. ;

Valentino, P. ;

Caldano, M. ;

Granieri, L. ;

Capobianco, M. ;

Malucchi, S. ;

Sala, A. ;

Marnetto, F. ;

Bertolotto, A. .

NEUROLOGY, 2008, 71 (24) :1940-1947

[4] Comparative study of four different assays for the detection of binding antibodies against interferon-β [J].

Gneiss, C. ;

Brugger, M. ;

Millonig, A. ;

Fogdell-Hahn, A. ;

Rudzki, D. ;

Hillert, J. ;

Berger, T. ;

Reindl, M. ;

Deisenhammer, F. .

MULTIPLE SCLEROSIS, 2008, 14 (06) :830-836

[5] Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference [J].

Hartung, HP ;

Munschauer, F ;

Schellekens, H .

EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (08) :588-601

[6] AN ANALYSIS OF NEUTRALIZATION REACTION OF INTERFERON BY ANTIBODY - A PROPOSAL ON THE EXPRESSION OF NEUTRALIZATION TITER [J].

KAWADE, Y .

JOURNAL OF INTERFERON RESEARCH, 1980, 1 (01) :61-70

[7] Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort [J].

McKay, F ;

Schibeci, S ;

Heard, R ;

Stewart, G ;

Booth, D .

JOURNAL OF IMMUNOLOGICAL METHODS, 2006, 310 (1-2) :20-29

[8] Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis:: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis [J].

Sorensen, PS ;

Deisenhammer, F ;

Duda, P ;

Hohlfeld, R ;

Myhr, KM ;

Palace, J ;

Polman, C ;

Pozzilli, C ;

Ross, C .

EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 (11) :817-827

← 1 →